{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:34:23Z","timestamp":1769758463567,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04249-8","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T14:44:33Z","timestamp":1753973073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Miguel A.","family":"Quiroz-Reyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick A.","family":"Quiroz-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Quiroz-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virgilio","family":"Lima-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"4249_CR1","first-page":"1","volume":"32","author":"LA Yannuzzi","year":"2012","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 2012;32:1\u20138.","journal-title":"Retina"},{"issue":"4","key":"4249_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/archopht.1997.01100150480005","volume":"115","author":"LA Yannuzzi","year":"1997","unstructured":"Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Archives of ophthalmology. 1997;115(4):478\u201385.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"4249_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","volume":"117","author":"LA Yannuzzi","year":"1999","unstructured":"Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Archives of ophthalmology. 1999;117(11):1503\u201310.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"4249_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","volume":"49","author":"AP Ciardella","year":"2004","unstructured":"Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Survey of ophthalmology. 2004;49(1):25\u201337.","journal-title":"Survey Ophthalmol"},{"key":"4249_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10384-007-0498-2","volume":"52","author":"SH Byeon","year":"2008","unstructured":"Byeon SH, Lee SC, Oh H-S, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Japanese journal of ophthalmology. 2008;52:57\u201362.","journal-title":"Japanese J Ophthalmol"},{"key":"4249_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00417-007-0575-8","volume":"245","author":"Y Liu","year":"2007","unstructured":"Liu Y, Wen F, Huang S, Luo G, Yan H, Sun Z, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology. 2007;245:1441\u20135.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"10","key":"4249_CR7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","volume":"121","author":"K Sho","year":"2003","unstructured":"Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Archives of Ophthalmology. 2003;121(10):1392\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"4249_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. American journal of ophthalmology. 2007;144(1):15-22.e2.","journal-title":"Am J Ophthalmol"},{"key":"4249_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s004170000180","volume":"238","author":"B Lafaut","year":"2000","unstructured":"Lafaut B, Leys A, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefe\u2019s archive for clinical and experimental ophthalmology. 2000;238:752\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"8","key":"4249_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364.","journal-title":"Retina."},{"key":"4249_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, Van Den Bergh H, Sickenberg M, Koh AH. Photodynamic therapy for polypoidal choroidal vasculopathy. Progress in retinal and eye research. 2013;37:182\u201399.","journal-title":"Progress Retinal Eye Res"},{"issue":"3","key":"4249_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/IAE.0b013e3181f274ec","volume":"31","author":"AA Rouvas","year":"2011","unstructured":"Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina. 2011;31(3):464\u201374.","journal-title":"Retina"},{"issue":"1","key":"4249_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ajo.2013.02.006","volume":"156","author":"T Sato","year":"2013","unstructured":"Sato T, Kishi S, Matsumoto H, Mukai R. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. American J Ophthalmol. 2013;156(1):95-105.e1.","journal-title":"American J Ophthalmol"},{"key":"4249_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00417-005-1139-4","volume":"243","author":"RM Silva","year":"2005","unstructured":"Silva RM, Figueira J, Cachulo ML, Duarte L, de Faria Abreu JR, Cunha-Vaz J. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology. 2005;243:973\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4249_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00417-007-0582-9","volume":"245","author":"K Sayanagi","year":"2007","unstructured":"Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefe\u2019s Arch Clin Exp Ophthalmol. 2007;245:1569\u201371.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"5","key":"4249_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/IAE.0b013e31816577cb","volume":"28","author":"E Akaza","year":"2008","unstructured":"Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008;28(5):717\u201322.","journal-title":"Retina."},{"issue":"6","key":"4249_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","volume":"156","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, et al. Effects of choroidal vascular hyperpermeability on anti\u2013vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. American Journal of Ophthalmology. 2013;156(6):1192-200.e1.","journal-title":"American J Ophthalmol"},{"issue":"4","key":"4249_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. American journal of ophthalmology. 2013;156(4):652-60.e1.","journal-title":"American J Ophthalmol"},{"key":"4249_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2415-13-43","volume":"13","author":"S Sonoda","year":"2013","unstructured":"Sonoda S, Sakamoto T, Otsuka H, Yoshinaga N, Yamashita T, Ki-I Y, et al. Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC ophthalmology. 2013;13:1\u20138.","journal-title":"BMC ophthalmology."},{"issue":"14","key":"4249_CR20","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1432\u201344.","journal-title":"New England J Med"},{"issue":"5","key":"4249_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","volume":"121","author":"A Oishi","year":"2014","unstructured":"Oishi A, Miyamoto N, Mandai M, Honda S, Matsuoka T, Oh H, et al. LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology. 2014;121(5):1151\u20132.","journal-title":"Ophthalmology."},{"issue":"7","key":"4249_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA ophthalmology. 2018;136(7):786\u201393.","journal-title":"JAMA ophthalmology."},{"key":"4249_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-016-0305-2","volume":"16","author":"GT Kokame","year":"2016","unstructured":"Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, et al. Prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. BMC ophthalmology. 2016;16:1\u201310.","journal-title":"BMC ophthalmology."},{"issue":"9","key":"4249_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4249_CR25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/OPTH.S87499","volume":"9","author":"AH Abd Elhamid","year":"2015","unstructured":"Abd Elhamid AH. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2277\u201383.","journal-title":"Clin Ophthalmol."},{"issue":"8","key":"4249_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/bjo.2007.128025","volume":"92","author":"MB Parodi","year":"2008","unstructured":"Parodi MB, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular edema in branch retinal vein occlusion: a pilot study. British J Ophthalmol. 2008;92(8):1046\u201350.","journal-title":"British J Ophthalmol"},{"issue":"1","key":"4249_CR27","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/s41598-021-82316-y","volume":"11","author":"SC Chi","year":"2021","unstructured":"Chi SC, Kang YN, Huang YM. Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1):2735.","journal-title":"Sci Rep."},{"issue":"5","key":"4249_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.survophthal.2023.04.002","volume":"68","author":"A Hatamnejad","year":"2023","unstructured":"Hatamnejad A, Patil NS, Mihalache A, Popovic MM, Kertes PJ, Muni RH, et al. Efficacy and safety of anti-vascular endothelial growth agents for the treatment of polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Surv Ophthalmol. 2023;68(5):920\u20138.","journal-title":"Surv Ophthalmol"},{"key":"4249_CR29","doi-asserted-by":"crossref","unstructured":"Sarvepalli SM, Kapoor I, Sarici K, Garg SJ, Hadziahmetovic M. Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis. Asia Pac J Ophthalmol (Phila). 2025;14(2):100173.","DOI":"10.1016\/j.apjo.2025.100173"},{"issue":"2","key":"4249_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajo.2013.04.001","volume":"156","author":"MY Lee","year":"2013","unstructured":"Lee MY, Lee WK, Baek J, Kwon OW, Lee JH. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor. American journal of ophthalmology. 2013;156(2):343\u20138.","journal-title":"American J Ophthalmol"},{"issue":"11","key":"4249_CR31","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"4249_CR32","first-page":"831","volume":"59","author":"AH Koh","year":"2018","unstructured":"Koh AH, Parikh S. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: 24-month results from the EVEREST II study. Invest Ophthalmol Vis Sci. 2018;59(9):831.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"4249_CR33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. American journal of ophthalmology. 2013;156(4):644-51.e1.","journal-title":"American J Ophthalmol"},{"key":"4249_CR34","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S171015","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, et al. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clin Ophthalmol. 2018. https:\/\/doi.org\/10.2147\/OPTH.S171015.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"4249_CR35","doi-asserted-by":"publisher","first-page":"e050252","DOI":"10.1136\/bmjopen-2021-050252","volume":"11","author":"CH Vyas","year":"2021","unstructured":"Vyas CH, Cheung CMG, Tan C, Chee C, Wong K, Jordan-Yu JMN, et al. Multicenter, randomized clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy. BMJ Open. 2021;11(7):e050252.","journal-title":"BMJ Open."},{"key":"4249_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0801-7","volume":"18","author":"K Lai","year":"2018","unstructured":"Lai K, Li Y, Zhou L, Zhong X, Huang C, Xu F, et al. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen. BMC ophthalmology. 2018;18:1\u20139.","journal-title":"BMC ophthalmology."},{"issue":"7","key":"4249_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994\u20139.","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"4249_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","volume":"65","author":"Y Ogura","year":"2021","unstructured":"Ogura Y, Iida T, Lee WK, Cheung CMG, Mitchell P, Leal S, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study. Jpn J Ophthalmol. 2021;65(3):344\u201353.","journal-title":"Jpn J Ophthalmol."},{"issue":"8","key":"4249_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015785","volume":"7","author":"JP Marques","year":"2017","unstructured":"Marques JP, Farinha C, Costa M, Ferr\u00e3o \u00c2, Nunes S, Silva R. Protocol for a randomized, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study. BMJ Open. 2017;7(8): e015785.","journal-title":"BMJ Open"},{"key":"4249_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4249_CR41","doi-asserted-by":"crossref","unstructured":"Qian T, Li X, Zhao M, Xu X. Polypoidal choroidal vasculopathy treatment options: A meta-analysis. European J Clin Invest. 2018;48(1).","DOI":"10.1111\/eci.12840"},{"issue":"1","key":"4249_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82316-y","volume":"11","author":"S-C Chi","year":"2021","unstructured":"Chi S-C, Kang Y-N, Huang Y-M. Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1): 2735.","journal-title":"Sci Rep"},{"key":"4249_CR43","doi-asserted-by":"crossref","unstructured":"Vadal\u00e0 M, Castellucci M, Guarrasi G, Cillino G, Bonfiglio VME, Casuccio A, et al. Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept. Int Ophthalmol. 2022:601\u201310.","DOI":"10.1007\/s10792-021-02032-4"},{"key":"4249_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-019-0310-1","volume":"20","author":"H-Y Weng","year":"2019","unstructured":"Weng H-Y, Huang T-L, Chang P-Y, Wang J-K. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy. BMC Pharmacol Toxicol. 2019;20:1\u20135.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"4249_CR45","doi-asserted-by":"publisher","first-page":"16461","DOI":"10.1038\/s41598-017-16476-1","volume":"7","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Sugiyama A, Yoneyama S, Tanabe N, Matsubara M, et al. Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy. Sci Rep. 2017;7(1):16461.","journal-title":"Sci Rep"},{"issue":"9","key":"4249_CR46","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/IAE.0000000000001765","volume":"38","author":"Y Kuroda","year":"2018","unstructured":"Kuroda Y, Yamashiro K, Ooto S, Tamura H, Oishi A, Nakanishi H, et al. Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration. Retina. 2018;38(9):1743\u201350.","journal-title":"Retina"},{"key":"4249_CR47","doi-asserted-by":"crossref","unstructured":"50. Arnold-Vangsted A, Schou MG, Balaratnasingam C, Cehofski LJ, Chhablani J, van Dijk EHC, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Acta Ophthalmol. 2024.","DOI":"10.1111\/aos.16797"},{"key":"4249_CR48","doi-asserted-by":"crossref","unstructured":"Bloom J, Madani R, Haidar AJ, Alasil T. Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo). J Vitreoretin Dis. 2024;8(6):24741264241271739.","DOI":"10.1177\/24741264241271739"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04249-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04249-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04249-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:52:30Z","timestamp":1757328750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04249-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4249"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04249-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki and received full approval from the appropriate research ethics committee, institutional review committee, and institutional teaching department (the institution did not provide reference numbers for conducting systematic review and network meta-analysis studies).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"440"}}